Honokiol, a bioactive compound derived from the bark of trees of the Magnolia genus, has emerged as a promising therapeutic agent in cancer treatment. Its wide range of biological properties includes antioxidant, anti-inflammatory, neuroprotective, and antitumor activities. This article delves into the role of honokiol in cancer treatment, supported by recent scientific findings.
Properties of Honokiol in Cancer Treatment
Honokiol enhances the efficacy of radiotherapy and chemotherapy, helping to overcome drug resistance.
Honokiol has the ability to cross cell membranes and the blood-brain barrier. This makes it especially useful in the treatment of brain tumors and intracranial metastases.
Its main mechanisms of antitumor action include:
Induction of Apoptosis: Honokiol promotes apoptosis (programmed cell death) through the activation of intrinsic and extrinsic pathways. Studies have shown that it acts by inhibiting various signaling pathways, including PI3K/AKT/mTOR and MAPK/ERK, which are essential for cell proliferation and cancer cell survival.
Tumor Modulation: It reduces angiogenesis (formation of new blood vessels), limiting the nutrient supply to the tumor. This is achieved by inhibiting vascular endothelial growth factor (VEGF).
Anti-inflammatory Effect: It decreases inflammation in the tumor microenvironment by suppressing mediators such as NF-κB and COX-2, which contribute to tumor growth and treatment resistance.
Scientific Evidence of Honokiol in the Treatment of Different Types of Cancer
Honokiol for Breast Cancer
In triple-negative breast cancer, honokiol showed specific cytotoxic effects against tumor cells by inducing oxidative stress and promoting apoptosis. It also improved the efficacy of chemotherapeutic drugs such as paclitaxel.
Honokiol for Lung Cancer
Reductions in tumor size have been reported in preclinical studies for lung cancer. Honokiol acts by inhibiting cell migration and invasion by reducing the activity of matrix metalloproteinases (MMPs).
Honokiol for Glioblastoma Multiforme
Glioblastoma is a type of brain tumor that is difficult to treat. Honokiol proved capable of crossing the blood-brain barrier and exerting cytotoxic effects through the inhibition of the STAT3 pathway, which is key to therapy resistance.
Honokiol for Ovarian Cancer
In in vivo experiments, honokiol has demonstrated inhibitory effects on the viability and proliferative capacity of ovarian cancer cells, provoked apoptotic responses (tumor cell death), and reduced the migratory and invasive tendencies of tumor cells.
Honokiol for Leukemias and Lymphomas
The compound has shown efficacy in hematological cancers such as leukemias and lymphomas. In acute myeloid leukemia, it increases sensitivity to conventional chemotherapeutic agents and reduces the cancer stem cell population.
Scientific Studies on Honokiol in Cancer Treatment
- Chen J, Zhang H et al. (2025) Honokiol in the treatment of triple-negative breast cancer: a network pharmacology approach and experimental validation. Biochem Biophys Res Commun. 2025 Jul 22;771:152008. doi: 10.1016/j.bbrc.2025.152008. Epub 2025 May 15. PMID: 40398092.
- Gao Q, Sheng Q et al. (2025). Honokiol-Magnolol-Baicalin Possesses Synergistic Anticancer Potential and Enhances the Efficacy of Anti-PD-1 Immunotherapy in Colorectal Cancer by Triggering GSDME-Dependent Pyroptosis. Adv Sci (Weinh). 2025 Apr;12(13):e2417022. doi: 10.1002/advs.202417022. Epub 2025 Feb 14. PMID: 39950759; PMCID: PMC11967828.
- Luo L et al (2024). Honokiol suppress the PD-L1 expression to improve anti-tumor immunity in lung cancer. Int Immunopharmacol. 2024 May 30;133:112098. doi: 10.1016/j.intimp.2024.112098. Epub 2024 Apr 15. PMID: 38626551.
- Liu F et al (2024). Honokiol regulates ovarian cancer cell malignant behavior through YAP/TAZ pathway modulation. J Obstet Gynaecol Res. 2024 Jun;50(6):1010-1019. doi: 10.1111/jog.15940. Epub 2024 Apr 4. PMID: 38576101.
- Wang J et al (2023). Use of honokiol in lung cancer therapy: a mini review of its pharmacological mechanism. J Asian Nat Prod Res. 2023 Nov;25(11):1029-1037. doi: 10.1080/10286020.2023.2193695. Epub 2023 Apr 3. PMID: 37010929.
- Mei M et al (2023). Honokiol prevents lung metastasis of triple-negative breast cancer by regulating polarization and recruitment of macrophages. Eur J Pharmacol. 2023 Nov 15;959:176076. doi: 10.1016/j.ejphar.2023.176076. Epub 2023 Oct 4. PMID: 37797675.
